Skip to main content
KYONGBO PHARMACEUTICAL CO., LTD. logo

KYONGBO PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 214390 ISIN · KR7214390007 LEI · 988400YKOM1CHDS6R917 KO Manufacturing
Open in API
Filings indexed 206 across all filing types
Latest filing 2023-02-20 AGM Information
Country KR South Korea
Listing KO 214390

About KYONGBO PHARMACEUTICAL CO., LTD.

https://www.kbpharma.co.kr/en/home

Kyongbo Pharmaceutical Co., Ltd. is a pharmaceutical company specializing in the research, development, and manufacturing of Active Pharmaceutical Ingredients (APIs) and finished drug products. The company also operates as a Contract Development and Manufacturing Organization (CDMO), offering integrated services from early-stage development through to commercial cGMP production. Its core product portfolio includes a diverse range of APIs, such as sterile and non-sterile cephalosporins, carbapenem antibiotics, and high-potency cytotoxic anti-cancer agents. In addition to APIs, the company manufactures finished dosage forms, including solid oral medications and sterile injectables. Kyongbo Pharmaceutical utilizes dedicated and segregated manufacturing facilities to produce its specialized product lines, supported by a strong commitment to research and innovation in API synthesis.

Recent filings

Filing Released Lang Actions
주주총회소집공고
AGM Information Classification · 100% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Kyongbo Pharmaceutical. It contains the meeting agenda, date, location, voting procedures, and management information (such as board activity and financial highlights). This document is a formal notice sent to shareholders to inform them of the upcoming Annual General Meeting (AGM) and to provide the necessary materials for their participation. Therefore, it is classified as AGM Information.
2023-02-20 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for Kyongbo Pharmaceutical. It outlines the date, location, and agenda items (such as financial statement approval, dividend declaration, and articles of incorporation changes). This type of document is a standard proxy solicitation/notice of meeting provided to shareholders to inform them of upcoming voting matters, which falls under the Proxy Solicitation & Information Statement category.
2023-02-15 Korean
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from Kyongbo Pharmaceutical regarding the decision to pay cash dividends. It specifies the dividend amount per share, the total dividend amount, the record date, and the date of the board resolution. This fits the definition of a 'Notice of Dividend Amount' (DIV) as it provides specific details regarding dividend payments to shareholders.
2023-02-15 Korean
매출액또는손익구조30%(대규모법인은15%)이상변경
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (Kyungbo Pharmaceutical) announcing a significant change (30% or more) in revenue or profit structure. This is a standard preliminary earnings disclosure required by the Korea Exchange (KRX) before the final audited annual report is released. It provides key financial highlights and explicitly states that the figures are subject to change upon final audit. It fits the definition of an Earnings Release (ER) as it provides initial highlights of financial results. FY 2022
2023-01-30 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders and special related parties (specifically regarding the cancellation of a gift of shares). This type of filing is used to notify the market of significant changes in shareholding thresholds and ownership structure, which falls under the 'Major Shareholding Notification' category.
2022-11-29 Korean
최대주주등소유주식변동신고서
Director's Dealing Classification · 100% confidence The document is a 'Report of Changes in Shareholding by Major Shareholders' (최대주주등소유주식변동신고서) filed by Kyongbo Pharmaceutical. It details specific transactions (cancellations of gifts/transfers) by company directors and their relatives. This falls under the category of 'Director's Dealing' (DIRS) as it reports personal share transactions by company insiders and major shareholders.
2022-11-29 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.